Validity of Celebrex Patents Upheld In Court, Barring Generics Until 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
ANDA filer Teva says it will appeal a federal court decision over the COX-2 inhibitor.
You may also be interested in...
Celebrex Reissue Patent Reawakens Generic Litigation
Pfizer sues five generic firms alleging their celecoxib ANDAs infringe a reissued method-of-use patent, which protects the blockbuster COX-2 inhibitor until December 2015, 18 months longer than had been expected.
Celebrex Adverse Events On FDA Pediatrics Committee Agenda In Late March
Celebrex adverse events will be reviewed by FDA Pediatrics Advisory Committee March 25; seven other drugs also on agenda.
Celebrex Adverse Events On FDA Pediatrics Committee Agenda In Late March
Celebrex adverse events will be reviewed by FDA Pediatrics Advisory Committee March 25; seven other drugs also on agenda.